« Previous
Next »
Titles
- Part D plans generally include drugs commonly used by dual eligibles: 20201
- Part D plans generally include drugs commonly used by dual eligibles: 20221
- Part D plans generally include drugs commonly used by dual-eligible enrollees: 20231
- Patient Safety Organizations: hospital participation, value, and challenges1
- Payment integrity: additional coordination is needed for assessing risks in the improper payment estimation process for advance premium tax credits : report to congressional requesters1
- Pennsylvania implemented our prior audit recommendations for critical incidents involving Medicaid enrollees with developmental disabilities but should continue to take action to reduce unreported incidents1
- Peripheral percutaneous transluminal angioplasty (PTA) and specialty catheters: premarket notification (510(k)) submissions : guidance for industry and Food and Drug Administration staff1
- Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry1
- Physician workforce: caps on Medicare-funded graduate medical education at teaching hospitals : report to Congressional requesters1
- Physician-hospital integration 2012: how health care reform is reshaping California's delivery system1
- Policy for monkeypox tests to address the public health emergency: guidance for laboratories, commercial manufacturers, and Food and Drug Administration staff1
- Policy for testing of alcohol (ethanol) and isopropyl alcohol for methanol: guidance for industry1
- Policy regarding N-acetyl-L-cysteine: guidance for industry1
- Postmarket surveillance under section 522 of the Federal Food, Drug, and Cosmetic Act: guidance for industry and Food and Drug Administration staff1
- Powers and possibilities of local boards of health1
- Prescription drug monitoring programs: views on usefulness and challenges of programs : report to Congressional committees1
- Prescription drugs: Department of Veterans Affairs paid about half as much as Medicare Part D for selected drugs in 2017 : report to the Ranking Member, Committee on the Budget, U.S. Senate1
- Prescription drugs: Medicare spending on drugs with direct-to-consumer advertising : report to Committee on the Judiciary, U.S. Senate1
- Prescription drugs: U.S. prices for selected brand drugs were higher on average than prices in Australia, Canada, and France : report to the Chairman, Committee on the Budget, U.S. Senate1
- Prescription opioids: Medicare needs to expand oversight efforts to reduce the risk of harm : report to Congressional requesters1